cytarabine has been researched along with bardoxolone methyl in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Andreeff, M; Chang, S; Estrov, Z; Gribble, G; Harris, D; Honda, T; Jackson, CE; Konopleva, M; Leysath, CE; May, WS; Munsell, M; Ruvolo, P; Sporn, MB; Stiouf, I; Suh, N; Tsao, T; Zhao, S | 1 |
1 other study(ies) available for cytarabine and bardoxolone methyl
Article | Year |
---|---|
Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia.
Topics: Annexin A5; Apoptosis; bcl-2-Associated X Protein; Blast Crisis; Caspase 3; Caspases; Cell Differentiation; Cell Survival; Cytarabine; DNA Fragmentation; Drug Interactions; Flow Cytometry; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Membrane Potentials; Mitogen-Activated Protein Kinases; Oleanolic Acid; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Retinoids; Tretinoin; Tumor Cells, Cultured | 2002 |